753 related articles for article (PubMed ID: 20431476)
21. pVHL and GSK3beta are components of a primary cilium-maintenance signalling network.
Thoma CR; Frew IJ; Hoerner CR; Montani M; Moch H; Krek W
Nat Cell Biol; 2007 May; 9(5):588-95. PubMed ID: 17450132
[TBL] [Abstract][Full Text] [Related]
22. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical expression of carbonic anhydrase 9, glucose transporter 1, and paired box 8 in von Hippel-Lindau disease-related lesions.
Chatzopoulos K; Aubry MC; Gupta S
Hum Pathol; 2022 May; 123():93-101. PubMed ID: 35196526
[TBL] [Abstract][Full Text] [Related]
24. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
Moch H
Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
[TBL] [Abstract][Full Text] [Related]
25. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
Zhang YT; Chen N; Zeng H; Zhou Q
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
[No Abstract] [Full Text] [Related]
26. The VHL-dependent regulation of microRNAs in renal cancer.
Neal CS; Michael MZ; Rawlings LH; Van der Hoek MB; Gleadle JM
BMC Med; 2010 Oct; 8():64. PubMed ID: 20964835
[TBL] [Abstract][Full Text] [Related]
27. VHL mutations and dysregulation of pVHL- and PTEN-controlled pathways in multilocular cystic renal cell carcinoma.
von Teichman A; Compérat E; Behnke S; Storz M; Moch H; Schraml P
Mod Pathol; 2011 Apr; 24(4):571-8. PubMed ID: 21151099
[TBL] [Abstract][Full Text] [Related]
28. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
29. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.
Pantuck AJ; An J; Liu H; Rettig MB
Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166
[TBL] [Abstract][Full Text] [Related]
30. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.
Mandriota SJ; Turner KJ; Davies DR; Murray PG; Morgan NV; Sowter HM; Wykoff CC; Maher ER; Harris AL; Ratcliffe PJ; Maxwell PH
Cancer Cell; 2002 Jun; 1(5):459-68. PubMed ID: 12124175
[TBL] [Abstract][Full Text] [Related]
31. Radiological evaluation, management, and surveillance of renal masses in Von Hippel-Lindau disease.
Meister M; Choyke P; Anderson C; Patel U
Clin Radiol; 2009 Jun; 64(6):589-600. PubMed ID: 19414081
[TBL] [Abstract][Full Text] [Related]
32. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
[TBL] [Abstract][Full Text] [Related]
33. Implication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis.
Serrano-Oviedo L; Giménez-Bachs JM; Nam-Cha SY; Cimas FJ; García-Cano J; Sánchez-Prieto R; Salinas-Sánchez AS
Urol Oncol; 2017 Mar; 35(3):114.e15-114.e22. PubMed ID: 27836247
[TBL] [Abstract][Full Text] [Related]
34. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
[TBL] [Abstract][Full Text] [Related]
35. VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors.
Schmitt AM; Schmid S; Rudolph T; Anlauf M; Prinz C; Klöppel G; Moch H; Heitz PU; Komminoth P; Perren A
Endocr Relat Cancer; 2009 Dec; 16(4):1219-27. PubMed ID: 19690016
[TBL] [Abstract][Full Text] [Related]
36. Mutational analysis of the von hippel lindau gene in clear cell renal carcinomas from tuberous sclerosis complex patients.
Duffy K; Al-Saleem T; Karbowniczek M; Ewalt D; Prowse AH; Henske EP
Mod Pathol; 2002 Mar; 15(3):205-10. PubMed ID: 11904337
[TBL] [Abstract][Full Text] [Related]
37. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma.
Ashida S; Nishimori I; Tanimura M; Onishi S; Shuin T
J Cancer Res Clin Oncol; 2002 Oct; 128(10):561-8. PubMed ID: 12384800
[TBL] [Abstract][Full Text] [Related]
38. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.
Kuehn EW; Walz G; Benzing T
Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376
[TBL] [Abstract][Full Text] [Related]
39. Low-grade renal carcinoma with histologic features overlapping with renal angiomyoadenomatous tumor and featuring polysomy 7 and 17 and a mutation in the von Hippel-Lindau gene: report of a hybrid tumor and a few comments on renal angiomyoadenomatous tumor and papillary renal tumors with clear cells.
Petersson F; Yan B; Huang J; Thamboo TP; Bing TK; Consigliere DT
Ann Diagn Pathol; 2011 Jun; 15(3):213-6. PubMed ID: 21396864
[No Abstract] [Full Text] [Related]
40. Novel insights into the role of the tumor suppressor von Hippel Lindau in cellular differentiation, ciliary biology, and cyst repression.
Wiesener MS; Maxwell PH; Eckardt KU
J Mol Med (Berl); 2009 Sep; 87(9):871-7. PubMed ID: 19629420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
